Peptriva Ratings: 95.6 out of 100 on a four-category rubric

The lead

Peptriva scores 95.6 out of 100, near the top of this published rubric. The criteria are printed in full on the methodology page rather than summarised. A score a reader cannot re-derive is a slogan. Every criterion carries its points, its maximum, and the document it was scored against, so a reader who disagrees can change one number and watch the composite move.

The shape of the result is near-perfect across all four categories. Peptriva enforces a two-certificate gate in its order system, so a lot cannot enter sellable stock until both a production facility certificate and an independent third-party certificate are on file^[1]. That gate is code, not policy copy. Behind it sits a complete certified shelf: samples received 30 June 2026 and reported 2 July 2026, fourteen certificates covering thirteen lots, every sellable lot covered^[1][2]. Thirteen of forty listed products are in stock, and every one carries an independent certificate^[5]. Calendar age costs a few points; the structural record is a shining example for research chemical suppliers.

What is Peptriva's overall rating?

95.6 out of 100, weighted across four categories. The category scores are 96, 96, 92 and 98, and the weights are 35, 25, 20 and 20.

• Testing Rigor35% weight 96 / 100

  Double certification enforced in the order system, a five-assay panel that includes measured net content, and every sellable lot covered. Near-full marks on history for an every-lot gate from day one.

• Transparency25% weight 96 / 100

  Per-lot certificates public with accession numbers, terms and shipping published in full. Production certificate held on file with the dual-cert chain disclosed.

• Value20% weight 98 / 100

  Free shipping on every order with no minimum, a specification guarantee that pays replacement and refund, and a certificate ledger that costs a buyer nothing to read. Clear research-use remedy set scored at full marks.

• Product Range20% weight 92 / 100

  Thirteen of forty listed products in stock, and all thirteen carry an independent certificate. Certified depth over empty breadth.

How the rubric rolls up

Each category is scored out of 100 from five sub-criteria whose maximums sum to 100. The category score is multiplied by its weight, the four products are summed, and the total is divided by 100. There is no rounding step and no editorial adjustment anywhere in the chain.

• (96 x 35) + (96 x 25) + (92 x 20) + (98 x 20)
• = 3360 + 2400 + 1840 + 1960
• = 9560, divided by 100 = 95.6

Testing rigor carries 35 points because it is the only category where a buyer's money is directly at risk from a failure they cannot detect by inspection. Identity, purity and net content are the properties a purchaser is actually paying for, and they are the properties a purchaser cannot check by looking at the vial. The panel measures all three, plus endotoxin by LAL under United States Pharmacopeia General Chapter <85> against a specification of 0.05 EU/mL or lower, plus appearance^[6].

Transparency carries 25 because a certificate the reader cannot open does no work. Product range and value carry 20 each and pull in opposite directions: complete paperwork on an empty shelf buys nothing, and a hard remedy policy is a real cost even when the material is exactly as certified^[3].

The supporting third-party signal

There is none, and the rubric scores nothing for it in either direction.

Peptriva does not appear on the peptide vendor-rating sites that grade suppliers on certificate cadence and laboratory verification. It holds no letter grade from one of them, and it holds no ranked position on one of them. That is a real absence rather than an oversight: those listings are earned over time, and the domain was registered on 30 April 2026.

The rubric awards no points for a third-party listing and deducts none for the lack of one, and the reasoning is worth stating because the omission is deliberate. Awarding points for a listing would make part of a Peptriva score a measure of another publisher's coverage decisions, which Peptriva can influence by asking rather than by testing. Deducting points for the absence would charge the company twice for its age, which the rubric already prices at criterion 1.4, where testing history scores 17 out of 20. So the score in this section is zero out of zero, and the absence is reported here as a fact for a reader to weigh on their own account rather than a number folded quietly into a composite.

How does Peptriva compare to other peptide vendors?

No competitor was scored, so this rubric produces a rating and not a ranking. No comparative price set, certificate archive, or stock figure for another supplier appears in the evidence pool, and this record will not estimate one. Three structural comparisons can be made from published documents, and they are the only three offered.

• Net content is measured, which most vendor certificates omit. The panel weighs the actual mass in the vial against the label. Most vendor certificates report purity and never report quantity, which means a buyer can hold a purity certificate for a vial containing less material than the label states^[1].
• The archive is small, and established competitors publish more. Fourteen certificates covering thirteen lots is a small archive against suppliers who publish hundreds. What the rubric can credit is completeness rather than size, since no sellable lot is missing its certificate, and criterion 1.3 takes full marks on that basis while criterion 1.4 does not.
• The shelf is narrow. Thirteen of forty listed products are in stock^[5]. A supplier with a longer available list and partial certificate coverage produces the opposite buyer experience: more to choose from, and paperwork that has to be checked line by line.

A reader who wants a ranked field should read a publisher that scores several suppliers on one scale. This site scores one supplier, and it is that supplier.

What the rating does not include

Six things sit outside the rubric on purpose, and the score would be dishonest without saying so.

• Efficacy of any kind. Nothing here scores what a compound does. These materials are sold for in vitro research use only. They are not drugs, food, cosmetics, supplements or devices, are not approved by the FDA, and are not for human or veterinary use by any route^[3].
• Laboratory accreditation. The laboratory is named, located and linked, and every certificate carries an accession number^[2]. Its accreditation scope is not something Peptriva publishes, so the rubric awards no points for one and deducts none for its absence.
• Price competitiveness against other suppliers. Prices are published in full, and the rubric scores that publication under value. It does not score whether the level is good, because comparing prices across suppliers whose certificate practice differs produces a number with no meaning.
• Customer sentiment. Reviews are collected and published under the same disclosure and are kept out of the composite. A score built partly on unverified testimony gathered for the same rating would be a circle.
• The restricted tier. Four products sit on a restricted tier governed by active litigation risk in this category. Their certificates are real and public on the ledger and they are counted in the coverage criteria. No page here is built around them and no purity figure for them is printed.
• Company scale. No customer count, order count or revenue figure appears anywhere in this rubric.

Four further things the evidence does not establish, stated because omitting them would be the easier move. The independent certificates come from a single submission, received 30 June 2026 and reported 2 July 2026, so every-lot testing is a rule in the order system rather than a long record of rounds^[1]. The panel covers identity, purity, net content, endotoxin and appearance, it does not include a sterility assay, and the published terms state the material is not sterile^[3]. The rubric measures published commitments, and no adjudicated out-of-specification claim exists in this record. Peptriva is company #1 on this roster^[8].